Rubedo首席科学官兼创始人Marco Quarta博士表示：“这是首批对一款靶向衰老相关病理细胞并促进健康细胞再生的衰老治疗药物（senotherapeutic drug）开展系统性评估的临床研究之一，同时也是GPX4调节剂首次进入人体临床试验。初步结果显示，该药物在作用机制层面符合预期，且在仅为期四周的试验中，其临床表现亦优于通常可预期水平。”他进一步表示：“我们对本项研究即将公布的完整数据 ...

The organizations that thrive during uncertain times are the ones who learn to keep moving even when visibility is limited.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to ...

WVE-007的安全性优势尤为明显，去年12月披露的数据也显示出一定的疗效潜力，但此次更新数据没有看到明确的量效关系，让资本市场对于INHBE siRNA的想象空间和热情有所下降。目前Arrowhead和Wave Life ...

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the ...

2025年第四季度营收同比大幅增长125%，达到2.93亿美元；每股收益为0.28美元，超出预期；毛利率从2024年第四季度的54%提高到75%。 分子分析服务营收同比增长199%，推动了强劲的业绩表现；调整后的EBITDA达到1.06亿美元，自由现金流为3970万美元。 盘后交易中，股价上涨0.87%至18.47美元，但较六个月前仍下跌50%，较52周高点42.50美元下跌55%。 分析师维持强 ...

What’s driving success for the UK’s life sciences businesses and what’s standing in their way? UK Life Sciences Future50 ...

Behavior Labs delivers intelligence from day zero using public, regulatory, and commercial data sources, then compounds in value as teams layer in their own strategic context — all within a secure, ...

Investing.com -- Kezar Life Sciences Inc. (NASDAQ:KZR) 股价周一上涨19.2%,此前 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) 宣布以每股6.955美元现金加或有价值权 (CVR)收购该公司。

Parimal Nathwani will manage the fund, which will directly invest in therapeutics and medical technology companies.

April 01, 2026 - PRESSADVANTAGE - As clinical research, pharmaceutical development, and medical device innovation ...

Track Suven Life Sciences share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and ...